FIG. 1



IL-6 (pg/ml)
IFN-γ (pg/ml)
IL-2 (pg/ml)
IL-8 (pg/ml)
Saline (n=6)
TGN1412-IgG4 (n=9)
TGN1412-AA (n=5)
(-)48h
(+)12h
(+)24h

FIG.1 continued




FIG. 2A




% of human cells out of CD45+ cells / blood
% CD3+ T cells
% CD19+ B cells
% CD56+ NK cells
% CD14+ Mono/Macro cells
(-)48h (+)12h (+)24h
Saline (n=6)
TGN1412-IgG4 (n=9)
TGN1412-AA (n=5)

FIG 2A continued






FIG. 2B



Absolute number of human cells / µl blood
CD3+ T cells
3500
3000
2500
2000
1500
1000
500
0
(-48h (+12h (+24h
Saline (n=6)
(-48h (+12h (+24h
TGN1412-IgG4 (n=9)
(-48h (+12h (+24h
TGN1412-AA (n=5)
Absolute number of human cells / µl blood
CD19+ B cells
1200
1000
800
600
400
200
0
(-48h (+12h (+24h
Saline (n=6)
(-48h (+12h (+24h
TGN1412-IgG4 (n=9)
(-48h (+12h (+24h
TGN1412-AA (n=5)

FIG. 2B continued




FIG. 2B continued




FIG. 3



Without IL-15 and FLT3L cytokine plasmid injection
IL-2 (pg/ml)
IL-6 (pg/ml)
IL-8 (pg/ml)
IFN-γ (pg/ml)
(-)48h
(+)2h
(+)24h
Saline (n=2)
TGN1412-IgG4 (n=7)

FIG. 3 continued




FIG. 4A



% of human cells out of CD45+ cells / blood
% CD3+ T cells
% CD19+ B cells
% CD56+ NK cells
% CD14+ Mono/Macro cells
(-)48h (+)2h (+)24h
Saline (n=2)
TGN1412-IgG4 (n=7)

FIG. 4A continued




FIG 4B




Absolute number of human cells / µl blood
CD3+ T cells
CD19+ B cells
(-)48h
(+)2h
(+)24h
Saline (n=2)
TGN1412-IgG4 (n=7)

FIG. 4B continued






FIG. 5



IL-6 (pg/ml)
IL-2 (pg/ml)
IFN-γ (pg/ml)
IL-8 (pg/ml)
(-)48h
(+)2h
(+)24h
Saline (n=3)
OKT3 (n=9)

FIG. 5 continued




FIG. 6A



% of human cells out of CD45+ cells / blood
% CD3+ T cells
% CD19+ B cells
% CD56+ NK cells
% CD14+ Mono/Macro cells
***
**
(-)48h (+)2h (+)24h
Saline (n=3)
OKT3 (n=7)

FIG. 6A continued




FIG. 6B




Absolute number of human cells / µl blood
CD3+ T cells
CD19+ B cells
1200
1000
800
600
400
200
0
***
*
(-)48h
(+)12h
(+)24h
Saline (n=3)
OKT3 (n=7)

FIG. 6B continued






FIG. 7



IL-6 (pg/ml)
IL-2 (pg/ml)
IFN-γ (pg/ml)
IL-8 (pg/ml)
(-)48h (+)2h (+)24h
Saline (n=2)
Alemtuzumab (n=7)

FIG. 7 continued




FIG. 8A



% of human cells out of CD45+ cells / blood
% CD3+ T cells
% CD19+ B cells
% CD56+ NK cells
% CD14+ Mono/Macro cells
(-)48h (+)2h (+)24h
Saline (n=2)
Alemtuzumab (n=5)
***
**
*

FIG. 8A continued




FIG. 8B



Absolute number of human cells / µl blood
CD3+ T cells
CD19+ B cells
Saline (n=2)
Alemtuzumab (n=5)
(-)48h
(+)12h
(+)24h
***
**

FIG. 8B continued




FIG. 8B continued




FIG. 9



IL-6 (pg/ml)
IFN-γ (pg/ml)
IL-2 (pg/ml)
IL-8 (pg/ml)
(-)48h (+)2h (+)24h
Saline (n=3)
Rituximab aCD20 (n=6)

FIG. 9 continued




FIG. 10A



% of human cells out of CD45+ cells / blood
% CD3+ T cells
% CD19+ B cells
% CD56+ NK cells
% CD14+ Mono/Macro cells
(-)48h (+)2h (+)24h
Saline (n=3)
Rituximab (n=6)
**
**

FIG. 10A continued




FIG. 10B




Absolute number of human cells / µl blood
CD3+ T cells
900
800
700
600
500
400
300
200
100
0
*
(-)48h
(+)12h
(+)24h
Saline (n=3)
(-)48h
(+)12h
(+)24h
Rituximab (n=6)
Absolute number of human cells / µl blood
% CD19+ B cells
1200
1000
800
600
400
200
0
**
**
(-)48h
(+)12h
(+)24h
Saline (n=3)
(-)48h
(+)12h
(+)24h
Rituximab (n=6)

FIG. 10B continued






FIG. 11A

FIG. 11B




FIG. 11C




FIG. 11D




FIG. 12A




FIG. 12B

FIG. 13




% of human cells out of CD45+ cells / spleen (+)24h
% CD3+ T cells
% CD4+ T cells
% CD8+ T cells
% CD19+ B cells
Saline (n=4)
TGN1412-IgG4 (n=8)
TGN1412-AA (n=4)
*

FIG. 13 continued






FIG. 13 continued




FIG. 13 continued




FIG. 14




% of human cells out of CD45+ cells / spleen (+)24h
% CD3+ T cells
% CD4+ T cells
% CD8+ T cells
% CD19+ B cells
Saline (n=2)
TGN1412-IgG4 (n=7)
Without IL-15 and FLT3L cytokine plasmid injection

FIG. 14 continued






FIG. 14 continued




FIG. 14 continued




FIG. 15



IL-2 (pg/ml)
3500
3000
2500
2000
1500
1000
500
0
IL-6 (pg/ml)
900
800
700
600
500
400
300
200
100
0
TNF-α (pg/ml)
14000
12000
10000
8000
6000
4000
2000
0
ns
-48h
+2h
+24h
Saline (n=8)
TGN1412-IgG4 (n=8)
TGN1412-AA (n=5)
OKT3 (n=9)
Alemtuzumab (n=7)
Rituximab (n=6)

FIG. 15 continued




FIG. 15 continued




FIG. 16A



CD3+ T Cells
CD19+ B Cells
CD14+ Mono/Macro Cells
-48h
+2h
+24h
Saline (n=8)
TGN1412-IgG4 (n=8)
TGN1412-AA (n=5)
OKT3 (n=9)
Alemtuzumab (n=7)
Rituximab (n=6)

FIG. 16A continue




FIG. 16B




FIG. 16C




FIG. 16D



% of human cells out of CD45+ cells / blood
% CD3+ T Cells
% CD19+ B Cells
-48h
+2h
+24h
Saline (n=8)
TGN1412-IgG4 (n=8)
TGN1412-AA (n=6)
OKT3 (n=9)
Alemtuzumab (n=7)
Rituximab (n=6)

FIG. 16D continue




FIG. 16E




FIG. 16F




FIG. 16G




FIG. 16H




FIG. 17



IL-2 (pg/ml)
IL-4 (pg/ml)
IL-1β (pg/ml)
IL-6 (pg/ml)
IFN-γ (pg/ml)
TNF-α (pg/ml)
IL-8 (pg/ml)
-48h
+2h
+24h
Saline (n=2)
TGN1412-IgG4 (n=7)

FIG. 18A



Absolute number of human cells/µl blood
CD3+ T Cells
CD56+ NK Cells
CD19+ B Cells
hCD45+ Cells
CD14+ Mono/Macro Cells
-48h
+2h
+24h
Saline (n=2)
TGN1412-IgG4 (n=7)

FIG. 18B





FIG. 18C






FIG. 18D




FIG. 18E




FIG. 18F




FIG. 18G




FIG. 18H




FIG. 19







IL-2 (pg/ml)
IFN-γ (pg/ml)
IL-6 (pg/ml)
IL-8 (pg/ml)
TNF-α (pg/ml)
IL-1β (pg/ml)
IL-4 (pg/ml)
-48h
+2h
+24h
Saline (n=2)
TGN1412-IgG4 (n=3)
OKT3 (n=4)

FIG. 20A


Absolute number of human cells/µl blood
CD3+ T Cells
800
700
600
500
400
300
200
100
0
*
*
-48h
+2h
+24h
Saline (n=2)
TGN1412-IgG4 (n=3)
OKT3 (n=4)


Absolute number of human cells/µl blood
CD56+ NK Cells
**
-48h
+2h
+24h
Saline (n=2)
TGN1412-IgG4 (n=3)
OKT3 (n=4)


Absolute number of human cells/µl blood
CD19+ B Cells
1200
1000
800
600
400
200
0
*
-48h
+2h
+24h
Saline (n=2)
TGN1412-IgG4 (n=3)
OKT3 (n=4)


Absolute number of human cells/µl blood
hCD45+ Cells
1000
900
800
700
600
500
400
300
200
100
0
*
-48h
+2h
+24h
Saline (n=2)
TGN1412-IgG4 (n=3)
OKT3 (n=4)



Absolute number of human cells/µl blood
CD14+ Mono/Macro Cells
120
100
80
60
40
20
0
**
-48h
+2h
+24h
Saline (n=2)
TGN1412-IgG4 (n=3)
OKT3 (n=4)

FIG. 20B




FIG. 20C




FIG. 20D




FIG. 20E




FIG. 20F




FIG. 20G




FIG. 20H




FIG. 21



IL-2 (pg/ml)
25
20
15
10
5
0
IFN-γ (pg/ml)
14
12
10
8
6
4
2
0
IL-6 (pg/ml)
1200
100
800
600
400
200
0
**
-48h
+2h
+24h
Saline (n=4)
TGN1412-IgG4 (n=3)
OKT3 (n=8)
Alemtuzumab (n=5)
Rituximab (n=4)

FIG. 22A




FIG. 22B




FIG. 22C




FIG. 22D




FIG. 23A





FIG. 23B



With IL-15 and FLT3L cytokine plasmid injection

FIG. 24




FIG. 24 continued









FIG. 24 continued












Without IL-15 and FLT3L cytokine plasmid injection

FIG. 25



Without IL-15 and FLT3L cytokine plasmid injection

FIG. 25 continued




FIG. 25 continued

